Buscador de publicacions

Publicacions

  • Gargallo P, Bautista F, Juan-Ribelles A, Izquierdo E, Soriano A, de Rojas T, Escudero A, Lavarino C, Solano P, Hladun R, Rubio-San-Simón A, Martínez-Romera I, Calabria I, Gene-Olaciregui N, Castañeda-Heredia A, de Álava E, Pérez-Martínez A, Astigarraga I, Patiño-García A, Alonso J, Fernández-Teijeiro A, Cañete A and Moreno L.

    Current status of precision medicine in pediatric oncology in Spain: a consensus report by the Spanish Society of Paediatric Haematology and Oncology (SEHOP)

    CLINICAL & TRANSLATIONAL ONCOLOGY . 24(5): 809-815. Nº de cites: 1

    [doi:10.1007/s12094-021-02759-7]

  • García-Domínguez DJ, Hajji N, López-Alemany R, Sánchez-Molina S, Figuerola-Bou E, Morón Civanto FJ, Rello-Varona S, Andrés-León E, Benito A, Keun HC, Mora J, Tirado ÓM, de Álava E and Hontecillas-Prieto L.

    Selective histone methyltransferase G9a inhibition reduces metastatic development of Ewing sarcoma through the epigenetic regulation of NEU1

    Oncogene . 41(18): 2638-2650. Nº de cites: 12

    [doi:10.1038/s41388-022-02279-w]

  • Alcon C, Martín F, Prada-Varela E, Mora J, Soriano A, Guillén G, Gallego S, Roma J, Samitier J, Villanueva A and Montero J.

    MEK and MCL-1 sequential inhibition synergize to enhance rhabdomyosarcoma treatment

    Cell Death Discovery . 8(1): 172-172. Nº de cites: 5

    [doi:10.1038/s41420-022-00959-w]

  • Gonçalves-Alves E, Garcia-López M, Rodriguez-Hernandez CJ, Gomez-Gonzalez S, Ecker RC, Suñol M, Muñoz-Aznar O, Carcaboso AM, Mora J, Lavarino C and Mateo-Lozano S.

    AC-265347 Inhibits Neuroblastoma Tumor Growth by Induction of Differentiation without Causing Hypocalcemia

    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES . 23(8): 4323. Nº de cites: 3

    [doi:10.3390/ijms23084323]

  • Castañeda-Heredia A, Gorostegui M, Miralles SL, ALICIA CHAMIZO BREMER, Patiño SC, Flores MA, Garraus-Oneca M, Lazaro JJ, Santa-María López V, Varo A, Muñoz JP and Mora J.

    How we approach the treatment of patients with high-risk neuroblastoma with naxitamab: experience from the Hospital Sant Joan de Deu in Barcelona, Spain

    ESMO Open . 7(2): 100462-100462. Nº de cites: 7

    [doi:10.1016/j.esmoop.2022.100462]

  • Inarejos E, Navarro OM, Navallas M, Enrique Ladera Gonzalez, Torner-Rubies F, Suñol M, Garraus-Oneca M, March JC and Barber-Martínez de la Torre I.

    Multiparametric MRI evaluation of bone sarcomas in children

    Insights into Imaging . 13(1): 33-33. Nº de cites: 4

    [doi:10.1186/s13244-022-01177-9]

  • Pascual-Pastó G, Castillo H, Unceta N, Aschero MR, Resa-Parés C, Gómez-Caballero A, Vilà-Ubach M, Muñoz-Aznar O, Suñol M, Burgeño-Sandoval V, Gomez-Gonzalez S, Sosnik A, Ibarra M, Schaiquevich P, de Álava E, Tirado OM, Mora J and Carcaboso AM.

    SPARC-mediated long-term retention of nab-paclitaxel in pediatric sarcomas

    JOURNAL OF CONTROLLED RELEASE . 342: 81-92. Nº de cites: 12

    [doi:10.1016/j.jconrel.2021.12.035]

  • Krauel L, Valls-Esteve A, Tejo-Otero A and Fenollosa-Artes F.

    3D-Printing in surgery: Beyond bone structures. A review

    Annals of 3D Printed Medicine . 4: 100039.

    [doi:10.1016/j.stlm.2021.100039]

  • Mesegue-Meda M, Alonso-Saladrigues A, Pérez-Jaume S, Comes-Escoda A, Dapena JL, Faura A, Conde N, Català-Temprano A, Ruiz-Llobet A, Zapico-Muñiz E, Camós-Guijosa M and Rives-Solà S.

    Lower incidence of clinical allergy with PEG-asparaginase upfront versus the sequential use of native E. coli asparaginase followed by PEG-ASP in pediatric patients with acute lymphoblastic leukemia.

    HEMATOLOGICAL ONCOLOGY . 39(5): 687-696. Nº de cites: 5

    [doi:10.1002/hon.2914]

  • Rubio-San-Simón A, Hladun Alvaro R, Juan Ribelles A, Castañeda-Heredia A, Guerra-García P, Verdú-Amorós J, Andrés M, Cañete A, Rives-Solà S, Pérez-Martínez A, Mora J, Patiño-García A, Lassaleta A, Llort A, Ramírez M, Mata C, Gallego S, Martín-Broto J, Cruz-Martínez O, Morales-La Madrid A, Solano P, Martínez Romera I, Fernández-Teijeiro A, Bautista F and Moreno L.

    The paediatric cancer clinical research landscape in Spain: a 13-year multicentre experience of the new agents group of the Spanish Society of Paediatric Haematology and Oncology (SEHOP)

    CLINICAL & TRANSLATIONAL ONCOLOGY . 23(12): 2489-2496. Nº de cites: 3

    [doi:10.1007/s12094-021-02649-y]